In African Americans, the genetic risk landscape for inflammatory bowel disease is very different from that of people with European ancestry, according to new findings.
These results of the first whole-genome study of inflammatory bowel disease (IBD) in African Americans show that future clinical research on IBD needs to take ancestry into account, say the researchers.
Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn’s disease and ulcerative colitis and more than 1,600 controls, appear in the
As part of their analysis, the researchers developed an algorithm that corrects for ancestry when calculating an IBD polygenic risk score. Polygenic risk scores are tools for calculating gene-based risk for a disease, which are used for IBD as well as other complex conditions such as coronary artery disease.
A team of scientific experts from across the U.S. and Puerto Rico are advocating for increased diversity in vaccine trials after publishing a new report that highlights a decade's worth of disparities.
E-Mail
In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans. The authors say that future clinical research on IBD needs to take ancestry into account.
Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn s disease and ulcerative colitis and more than 1,600 controls, were published on February 17 in the
American Journal of Human Genetics.
As part of their analysis, the researchers developed an algorithm that corrects for ancestry when calculating an IBD polygenic risk score. Polygenic risk scores are tools for calculating gene-based risk for a disease, which are used for IBD as well as other complex conditions such as coronary artery disease.
New study highlights lack of diversity and inclusion in vaccine clinical trials
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed Anthony Jackson, security coordinator for Fred Hutchinson Cancer Research Center, receives a dose of the new Pfizer-BioNTech COVID-19 vaccine on Jan. 19, 2021, at a new vaccine clinic set up on the Fred Hutch campus. Robert Hood
SEATTLE February 19, 2021 A team of scientific experts from across the U.S. and Puerto Rico are advocating for increased diversity in vaccine trials after publishing a new report that highlights a decade’s worth of disparities. The new study, published in JAMA Network Open, found that among U.S.-based vaccine clinical trials, people who are Black/African American, American Indian/Alaska Native, Hispanic/Latino and age 65 and older were the most underrepresented groups. Conversely, adult women
Most vaccine trials fail to report data on participant ethnicity or race statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.